|
- Contact Us | Retina Vitreous Associates Medical Group
Los Angeles 1245 Wilshire Blvd, Ste 380 Los Angeles, CA 90017 Phone: (213) 483-8810 Fax: (213) 481-1503
- Firas Rahhal, M. D. | Retina Vitreous Associates Medical Group
Dr Rahhal is currently a partner at Retina-Vitreous Associates Medical Group in Los Angeles and is an Associate Clinical Professor of Ophthalmology at the UCLA School of Medicine – Jules Stein Eye Institute He is an extremely busy and respected clinician and clinical researcher
- Our Physicians | Retina Vitreous Associates Medical Group - laretina. com
Each doctor in our group is board certified in ophthalmology and has completed formal sub-specialty training in medical and surgical diseases of the retina, vitreous, and macula
- David S. Boyer, M. D. | Retina Vitreous Associates Medical Group
Retina-Vitreous Associates Medical Group Diseases | Surgery of the Retina and Vitreous Retina-Vitreous Associates Medical Group Retina-Vitreous Associates Medical Group 213-483-8810 Our Physicians Our Physicians Overview David S Boyer, M D Thomas G Chu, M D Firas Rahhal, M D
- New Patients | Retina Vitreous Associates Medical Group
Retina-Vitreous Associates Medical Group specializes in the treatment of diseases affecting the back of the eye, specifically those of the retina, vitreous, and macula Patients are typically referred by their general ophthalmologist when a retinal problem is suspected
- Daniel D. Esmaili, M. D. | Retina Vitreous Associates Medical Group
Dr Daniel D Esmaili is a board-certified ophthalmologist specializing in the medical and surgical treatment of diseases of the retina and vitreous
- David S. Liao, M. D. | Retina Vitreous Associates Medical Group
Dr David S Liao is a board-certified ophthalmologist specializing in the medical and surgical treatment of diseases of the retina and vitreous
- Clinical Trials | Retina Vitreous Associates Medical Group - laretina. com
Retina-Vitreous Associates Medical Group has participated in clinical research for over 15 years and is committed to the development of novel diagnostic and therapeutic modalities for retinal disease
|
|
|